FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
GEMS™ WIN Software and HeartCheck™ Sales Will Have Expanded Access into the United States Air Force and Other Military Establishments
Toronto, Canada – CardioComm Solutions, Inc. (TSX-V:EKG) (“CardioComm Solutions” or the “Company”),CardioComm Solutions today announced that it has become an approved vendor for the sale of their HeartCheck™ products and ECG-based software solutions into numerous organizations within the umbrella of the U.S. Federal Government. As an active registrar in the U.S. Federal Government's System for Award Management (SAM), CardioComm Solutions is now eligible for contracts, assistance awards and to do business with the U.S. Federal Government and their agencies globally.
The approval process requires several levels of reviews from organizations such as Dun & Bradstreet, the Department of Defense's Defense Logistics Agency and the Internal Revenue Service. As a non-US based organization, the Company also secured a NATO Commercial & Government Entity Code (NCAGE) which is used extensively in various procurement, codification and logistics functions throughout the Federal Government as well as by over 20 countries worldwide. One of its primary purposes is to identify potential sources of supply for items being acquired by the military forces of these countries.
The expanded exposure for the sales of CardioComm Solutions GEMS™ WIN and HeartCheck™ ECG products opens up an important sector within the U.S. market. Following the finalization of CardioComm Solutions' approval, the Company confirms the first SAM-based sale of its recently released GEMS™ software into a U.S. Military Medical Centre located in Europe. The current disclosure follows closely a recent press release announcing CardioComm Solutions' listing by the FAA Civil Aerospace Medical Institute as an ECG Cloud Service provider for use by Air Medical Examiners.
CardioComm Solutions' executive management confirms that additional GEMS™ WIN license purchase reviews are underway within U.S. Federal Military bases and medical centers and that they are working with additional departments within the U.S. Military and Veteran Affairs for securing further approvals and preferred vendor status clearances. Further updates will be provided by the Company.
To learn more about the CardioComm Solutions products please see the Company's website www.cardiocommsolutions.com.
CardioComm Solutions' patented and proprietary
technology is used in products for recording,
viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products
are sold worldwide through a combination of an
external distribution network and a North
American-based sales team. The Company has
earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA
market clearance for its software devices.
CardioComm Solutions is headquartered in
Toronto, Canada, with offices in Victoria,
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking
statements and forward looking information with
respect to the financial condition, results of
operations and business of CardioComm Solutions
and certain of the plans and objectives of
CardioComm Solutions with respect to these
items. Such statements and information reflect
management's current beliefs and are based on
information currently available to management.
By their nature, forward-looking statements and
forward-looking information involve risk and
uncertainty because they relate to events and
depend on circumstances that will occur in the
future and there are many factors that could
cause actual results and developments to differ
materially from those expressed or implied by
these forward-looking statements and
In evaluating these statements, readers should:
specifically consider risks discussed under the
heading "Risk Factors" in the Company's Annual
Information Form, available at www.sedar.com;
not to place undue reliance on forward-looking
statements and forward-looking information; be
aware. the Company does not assume any
obligation to update the forward-looking
statements and forward-looking information
contained in this Annual Information Form other
than as required by applicable laws (including
without limitation Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of